| HOME >> MEDICINE >> TECHNOLOGY |
4.3.4.7 Annual Cost of Therapy
4.3.4.8 Product Positioning
4.3.4.9 Sales Forecast
4.3.5 Eloxatin (oxaliplatin)
4.3.5.1 Overview
4.3.5.2 Efficacy
4.3.5.3 Safety
4.3.5.4 Clinical Study Details
4.3.5.5 Regulatory Approvals
4.3.5.6 Life Cycle Management Activities
4.3.5.7 Annual Cost of Therapy
4.3.5.8 Product Positioning
4.3.5.9 Sales Forecast
4.3.6 Camptosar (irinotecan)
4.3.6.1 Overview
4.3.6.2 Efficacy
4.3.6.3 Safety
4.3.6.4 Clinical Study Details
4.3.6.5 Annual cost of Therapy
4.3.6.6 Regulatory approvals
4.3.6.7 Life Cycle Management Activities
4.3.6.8 Sales forecast
4.3.7 Fluorouracil (5-FU)
4.3.7.1 Overview
4.3.7.2 Efficacy
4.3.7.3 Safety
4.3.7.4 Annual Cost of Therapy
4.3.8 Leucovorin (folinic acid)
4.3.8.1 Overview
4.3.8.2 Efficacy
4.3.8.3 Safety
4.3.8.4 Annual Cost of Therapy
4.4 Key Takeaway
5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Colorectal Cancer Pipeline
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline
5.5.3 Failure of key Molecules in Phase II and Phase III Development
5.6 Partners in Development
5.6.1 Licensing Agreements by Phase of Development
5.6.1.1 Morphotek Enters Into Exclusive License Agreement with National Cancer Institute
5.6.1.2 AVEO Pharmaceuticals Enters Into Licensing Agreement with Kirin Brewery
5.6.1.3 Access Pharmaceuticals Enters Into Licensing Agreement with Jiangsu Ao
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |